Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Dr. Flea's blog
Nurse at small
Your Child's Health Blog
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Monday, March 26, 2007
Contrast agent may shed light on breast cancer diagnosis
Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School are reporting preliminary success with a new way to screen for breast cancer that one day might supplement mammography, according to the American Chemical Society.
Dr. John Frangioni and researchers in his lab have developed a way to make a contrast agent that after being injected into the bloodstream binds to a particular calcium salt called hydroxyapatite.
That salt is found in malignant micro-calcifications in the breast, but not in benign ones, according to an ACS statement. The contrast agents are designed to be used with optical tomography, an imaging method that sends near-infrared light through the body. Frangioni said it would likely be a few years before the compound is tested in human trials.
Kumar R. Bhushan, a postdoctoral fellow in Frangioni's lab, is scheduled to present the details today at the ACS meeting in Chicago.